View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2016	Mar. 13, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Entity Registrant Name	TAPIMMUNE INC
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 36,554,500
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		8,439,166

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash	$ 7,851,243	$ 6,576,564
Prepaid expenses and deposits	70,149	68,803
Total Assets	7,921,392	6,645,367
Current Liabilities
Accounts payable and accrued liabilities	1,224,940	967,358
Research agreement obligations	492,365	492,365
Warrant liability	14,500	26,493,000
Promissory notes	5,000	30,000
Promissory note, related party	0	23,000
Total Liabilities	1,736,805	28,005,723
Commitments and Contingencies
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized:	0	0
Common stock, $0.001 par value, 41,666,667 shares authorized, 8,421,185 and 5,882,955 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively	8,421	5,884
Additional paid-in capital	151,991,974	112,142,187
Accumulated deficit	(145,815,808)	(133,508,427)
Total stockholders’ equity (deficit)	6,184,587	(21,360,356)
Total liabilities and stockholders’ equity (deficit)	7,921,392	6,645,367
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized:	0	0
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value — 5,000,000 shares authorized:	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,666,667	41,666,667
Common stock shares issued	8,421,185	5,882,955
Common stock shares outstanding	8,421,185	5,882,955
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Operating expenses:
Research and development	$ 3,800,035	$ 1,711,177
General and administrative	4,692,234	4,447,781
Loss from Operations	(8,492,269)	(6,158,958)
Other Income (Expense)
Changes in fair value of warrant liabilities	5,939,500	(27,872,585)
Foreign exchange gain	0	775
Grant income	231,200	0
Interest and financing charges	0	(10,925)
Loss on debt settlement agreement	(135,640)	(24,697)
Other income	1,828	0
Net Loss	$ (2,455,381)	$ (34,066,390)
Basic net loss per share	$ (0.36)	$ (9.3)
Diluted net loss per share	$ (0.72)	$ (9.3)
Weighted Average Number of Common Shares Outstanding, Basic	6,889,898	3,662,256
Weighted Average Number of Common Shares Outstanding, Diluted	7,420,995	3,662,256

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2014	$ (1,023,636)	$ 1,695	$ 85,284,400	$ (86,309,731)
Beginning Balance, Share at Dec. 31, 2014		1,693,238
Accounts payable settled in shares, Amount	21,913	$ 10	21,903	0
Accounts payable settled in shares, Share		9,871
Private placement (net of finders' fee), Amount	2,326,015	$ 1,028	2,324,987	0
Private placement (net of finders' fee), Share		1,030,288
Fair value of warrants recognized as derivative liabilities in January and March 2015 Financing	(9,313,000)	$ 0	(2,313,694)	(6,999,306)
Fair value of warrants issued on May 28, 2015	(6,133,000)	0	0	(6,133,000)
Exercise of warrants, Amount	9,219,998	$ 3,094	9,216,904	0
Exercise of warrants, Share		3,090,000
Finders’ fee on exercise of warrants	(767,995)	$ 0	(767,995)	0
Reclassification of fair value of warrant liabilities at exercise date	16,835,000	0	16,835,000	0
Shares issued in debt settlement agreements, Amount	26,473	$ 5	26,468	0
Shares issued in debt settlement agreements, Share		4,163
Stock- based compensation, Amount	1,514,266	$ 52	1,514,214	0
Stock- based compensation, Share		51,676
Net loss	(34,066,390)	$ 0	0	(34,066,390)
Adjustment for rounded shares due to reverse stock split		3,719
Ending Balance, Amount at Dec. 31, 2015	(21,360,356)	$ 5,884	112,142,187	(133,508,427)
Ending Balance, Share at Dec. 31, 2015		5,882,955
Issuance of common stock in private placement, Amount	3,135,196	$ 653	3,134,543	0
Issuance of common stock in private placement, Share		653,187
Finders’ fee and legal costs relating to private placements	(804,070)	$ 0	(804,070)	0
Fair value of shares issued as inducement on August 10, 2016, Amount	0	$ 750	4,499,250	(4,500,000)
Fair value of shares issued as inducement on August 10, 2016, Share		750,000
Fair value of series F and F-1 warrants issued as inducement in August 2016	0	$ 0	5,352,000	(5,352,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	0	15,465,000	0
Exercise of warrants, Amount	6,000,000	$ 1,000	5,999,000	0
Exercise of warrants, Share		1,000,000
Finders’ fee on exercise of warrants	(516,651)	$ 0	(516,651)	0
Reclassification of fair value of warrant liabilities at exercise date	5,074,000	0	5,074,000	0
Exercise of stock options, Amount	$ 18,125	$ 10	18,115	0
Exercise of stock options, Share	10,417	10,417
Shares issued in debt settlement agreements, Amount	$ 70,315	$ 10	70,305	0
Shares issued in debt settlement agreements, Share		10,191
Stock- based compensation, Amount	1,558,409	$ 114	1,558,295	0
Stock- based compensation, Share		114,435
Net loss	(2,455,381)	$ 0	0	(2,455,381)
Ending Balance, Amount at Dec. 31, 2016	$ 6,184,587	$ 8,421	$ 151,991,974	$ (145,815,808)
Ending Balance, Share at Dec. 31, 2016		8,421,185

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Cash flow from operating activities
Net loss	$ (2,455,381)	$ (34,066,390)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of warrant liabilities	(5,939,500)	27,872,585
Loss on debt settlement agreements	70,315	24,697
Non-cash interest and finance charges	0	10,925
Stock-based compensation	1,558,409	1,705,067
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(1,346)	13,701
Accounts payable and accrued liabilities	257,582	96,018
Net cash used in operating activities	(6,509,921)	(4,343,397)
Cash flow from financing activities
Private placements	3,135,196	2,464,000
Finders’ fee and legal costs on private placements	(804,070)	(137,985)
Repayment of promissory note	(25,000)	0
Repayment of promissory note - related party	(23,000)	0
Proceeds from exercise of stock options	18,125	0
Proceeds from exercise of warrants	6,000,000	9,219,998
Finders' fee on exercise of warrants	(516,651)	(767,996)
Net cash provided by financing activities	7,784,600	10,778,017
Net increase in cash	1,274,679	6,434,620
Cash, beginning of year	6,576,564	141,944
Cash, end of year	7,851,243	6,576,564
Supplemental disclosure of cash flow information
Cash paid for interest	0	0
Cash paid for taxes	0	0
Supplemental schedule of non-cash investing and financing activities:
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson’s compensation	191,000	0
Accounts payable settled in common stock	0	22,000
Fair value of issuance of series F and F-1 warrants as inducement in August 2016	5,352,000	0
Fair value of shares issued as inducement on August 10, 2016	4,500,000	0
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	15,465,000	0
Fair value of issuance of warrants in January and March 2015 financing	0	9,313,000
Issuance of additional warrants in May 28, 2015 transaction	0	6,133,000
Reclassification of Derivative Warrant Liabilities to Equity at exercise date	$ 5,074,000	$ 16,835,000

NATURE OF OPERATIONS

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1:

Nature of Operations

TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

A Phase I study at the Mayo Clinic, Rochester, MN, evaluating the safety and immune responses of a set of proprietary HER2/neu+ antigens has been successfully completed and the results led to the decision to proceed with Phase II clinical studies in 2017.

A separate Phase I study has also been conducted at Mayo Foundation (“Mayo”) in ovarian and breast cancer (Folate Receptor Alpha). Folate Receptor Alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. In the USA alone, there are approximately 30,000 ovarian cancer patients newly diagnosed every year. These Folate Receptor Antigens are applicable to ovarian and triple-negative breast cancer. Both of these diseases have few treatment options if any beyond surgery and chemotherapy and therefore the Company is hopeful that it might be an ideal candidate for orphan drug status in these indications. This study has been successfully completed and the results led to the decision to proceed with multiple Phase II studies in 2017.

In addition, enhancing the visibility of cancer or infected cells to a patient’s immune system is a critical aspect of an effective vaccine. In this regard, TapImmune’s Polystart™ nucleic acid-based technology provides a four-fold increase in target cell specific naturally processed antigenic epitopes on a cells surface. This increased cell surface presentation corresponding increases activated Helper and/or long-lived Killer T-cell populations that then effectively seek out and work to destroy a patient’s cancer cells.

Liquidity, financial condition and managements plans

These consolidated financial statements have been prepared on the basis of a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As at December 31, 2016, the Company had cash balances of approximately $7,851,000. Historically, the Company has incurred significant losses in the development of its business. The ability of the Company to continue as a going concern is dependent on raising additional capital to fund current clinical trials, ongoing research and development, maintenance and protection of patents and ultimately on generating future profitable operations. Planned expenditures relating to current and future clinical trials of the Company’s immunotherapy vaccine will require significant additional funding. The Company is dependent on future financings to fund ongoing research and development as well as working capital requirements. The Company’s future capital requirements will depend on many factors including the rate and extent of scientific progress in its research and development programs, the timing, cost and scope involved in clinical trials, obtaining regulatory approvals, pursuing further patent protections and the timing and costs of commercialization activities.

Management is addressing going concern remediation through seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements.

Historically the Company has raised capital through issuances of various financial instruments and during 2016, the Company completed significant restructuring of outstanding debt and equity instruments into equity. Additional capital is required to expand programs including pre-clinical work and to progress clinical trials for the lead vaccine candidates. Strategic partnerships will be needed to continue the product development portfolio and fund development costs. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company beyond the next twelve months.

There is no certainty that the Company will be able to arrange sufficient funding to continue development of products to marketability.

Reverse stock split

On September 13, 2016, the Company’s Board of Directors approved a 1-for-12 reverse stock split of the Company’s authorized and issued and outstanding common stock. The reverse stock split became effective on September 16, 2016. Upon the effectiveness of the reverse stock split, (i) every twelve shares of outstanding common stock was combined into one share of common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased and (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased. All historical share and per share amounts reflected in this annual report have been adjusted to reflect the reverse stock split.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 2:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

These financial statements include the accounts of the Company and its wholly-owned and dormant subsidiary GeneMax Pharmaceuticals Inc. All significant intercompany balances and transactions are eliminated upon consolidation.

Use of Estimates

Preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.

Fair Value Measurements

The Company follows Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”) for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows:

⋅ Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

⋅ Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

⋅ Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial Instruments and Concentration of Credit Risk.

Patents and Patent Application Costs

Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.

Stock-Based Compensation

The Company follows the provisions ASC 718, “Compensation – Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors and consultants, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period and are recorded in general and administrative expenses. For stock options and warrants granted in consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505, “Equity”. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is being re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period will be adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested.

Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Expected Term — The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend — The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.

Research and Development Costs

The Company has acquired research and development rights to certain technologies. The rights and licenses acquired are considered rights to unproven technology which may not have alternate future uses and therefore, are expensed as incurred as research and development costs.

Clinical trial expenses include direct costs associated with contract research organizations (“CROs”), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved.

The Company incurred costs of approximately $3,800,000 and $1,711,000 on research and development for the year ended December 31, 2016 and 2015, respectively.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.

Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of December 31, 2016 and 2015, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2016 and 2015.

Derivative Liability

The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. This accounting treatment requires that the carrying amount of embedded derivatives be marked-to-market at each balance sheet date and carried at fair value. In the event that the fair value is recorded as a liability, the change in fair value during the period is recorded in the Statement of Operations as either income or expense. Upon conversion, exercise or modification to the terms of a derivative instrument, the instrument is marked to fair value at the conversion date and then the related fair value is reclassified to equity.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The classification of financial instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Management must determine whether an instrument (or an embedded feature) is indexed to the Company’s own stock. An entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. This exercise affects the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible notes containing full-ratchet and anti-dilution protections (iii) certain free standing warrants that contain contingently puttable cash settlement.

Grant Income

The Company recognizes grant income in accordance with the terms stipulated under the grant awarded to the Company’s collaborators at the Mayo Foundation from the U. S. Department of Defense. In various situations, the Company receives certain payments from the U.S. Department of Defense for reimbursement of clinical supplies. These payments are non-refundable, and are not dependent on the Company’s ongoing future performance. The Company has adopted a policy of recognizing these payments as grant income when received.

Earnings (Loss) per Common Share

Basic earnings (loss) per share include only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted earnings per share include the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.

Cash and Credit Risk

The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits of $250,000. As of December 31, 2016 and 2015, approximately $7.6 million and $6.3 million, respectively, in cash was uninsured based upon the FDIC insurance coverage limits.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Statement of Cash Flows

In August 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-15, Statement of Cash Flows (Topic 230). This amendment provides guidance on the presentation and classification of specific cash flow items to improve consistency within the statement of cash flows. ASU 2016-15 is effective for fiscal years, and interim periods within those fiscal years beginning after December 15, 2017, with early adoption permitted. The Company is evaluating the effect that ASU 2016-15 will have on its financial statements and related disclosures.

Going Concern

In August 2014, the FASB issued ASU No. 2014-15, ”Presentation of Financial Statements-Going Concern”, which defines management's responsibility to assess an entity's ability to continue as a going concern, and requires related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. ASU No. 2014-15 is effective for the Company for the fiscal year ending on December 31, 2016, with early adoption permitted. The Company adopted ASU 2014-15 as of December 31, 2016 in its consolidated financial statements and related disclosures, which did not have a material impact on its results of operations, cash flows or financial position.

Deferred Taxes

In November 2015, FASB issued ASU No. 2015-17, ”Balance Sheet Classification of Deferred Taxes”. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU No. 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted ASU No. 2015-17 on January 1, 2017 and its adoption did not have a material impact on the Company’s financial position and results of operations.

Compensation-Stock Compensation

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. Under ASU No. 2016-09, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in capital (“APIC”). Instead, they will record all excess tax benefits and tax deficiencies as income tax expense or benefit in the income statement and the APIC pools will be eliminated. In addition, ASU No. 2016-09 eliminates the requirement that excess tax benefits be realized before companies can recognize them. ASU No. 2016-09 also requires companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Furthermore, ASU No. 2016-09 will increase the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation. An employer with a statutory income tax withholding obligation will now be allowed to withhold shares with a fair value up to the amount of taxes owed using the maximum statutory tax rate in the employee’s applicable jurisdiction(s). ASU No. 2016-09 requires a company to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on the statement of cash flows. Under current U.S. GAAP, it was not specified how these cash flows should be classified. In addition, companies will now have to elect whether to account for forfeitures on share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. The amendments of this ASU are effective for reporting periods beginning after January 1, 2017, with early adoption permitted but all of the guidance must be adopted in the same period. The Company adopted this on January 1, 2017. The Company has evaluated the impact of ASU No. 2016-09 and has determined that the adoption of the impact of forfeitures, net of income taxes, will not have a material impact on the Company’s future financial statements.

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

12 Months Ended

Dec. 31, 2016

Noncontrolling Interest [Abstract]

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Note 3:

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Net Loss per Share Applicable to Common Stockholders

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of loss per share for the years ended December 31, 2016 and 2015, respectively:

	For the years ended
	December 31,
	2016		2015
Net loss	$	(2,455,381)	$	(34,066,390)
Less: Non cash income from changes in fair value of derivative liabilities		(2,856,000)		-
Net loss - diluted	$	(5,311,381)	$	(34,066,390)

Weighted average common shares outstanding - basic		6,889,898		3,662,256
Common stock warrants		531,097		-
Weighted average common shares outstanding - diluted		7,420,995		3,662,256

Net loss per share data:
Basic	$	(0.36)	$	(9.30)
Diluted	$	(0.72)	$	(9.30)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	For the years ended
	December 31,
	2016		2015
Common stock options		434,000		299,000
Common stock warrants - equity treatment		5,054,000		212,000
Common stock warrants - liability treatment		4,000		4,130,000
Potentially dilutive securities		5,492,000		4,641,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Note 4: accounts payable and accrued liabilities

Accounts payable and accrued liabilities consist of the following as of December 31, 2016 and 2015, respectively:

	For the years ended
	December 31,
	2016		2015
Accounts payable	$	680,181	$	691,094
Compensation and benefits		217,622		191,000
Professional fees		53,428		15,000
Consulting agreements		94,576		-
Technology license fees		105,000		-
Other		74,133		70,264
Total accounts payable and accrued liabilities	$	1,224,940	$	967,358

RESEARCH AGREEMENTS

12 Months Ended

Dec. 31, 2016

Research and Development [Abstract]

RESEARCH AGREEMENTS

Note 5:

Research Agreements

Crucell Holland B. V. (“Crucell”) – Research License and Option Agreement

In 2003 and further amended in 2008 the Company acquired a research license and option agreement from Crucell for use of an adenoviris technology. The Company has not made use of the technology in its current work and has not asked for nor received any work product from Crucell. Crucell was acquired by Johnson and Johnson in 2010.

As of December 31, 2016 and 2015, the Company has accrued $492,000 as amounts owed under the amended agreement.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

WARRANT LIABILITY

12 Months Ended

Dec. 31, 2016

Warrant Liability [Abstract]

WARRANT LIABILITY

Note 6:

WARRANT LIABILITY

A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the years ended 2016 and 2015 is as follows:

Stock Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Year Ending December 31, 2016			For the Year Ending December 31, 2015
Exercise price	$	1.20		$	0.74
Contractual term (years)		1.15			4.2
Volatility (annual)		100	%		155	%
Risk-free rate		1.00	%		2.00	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are recalculated every reporting period and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

The following table presents changes in Level 3 warrant liabilities measured at fair value for the year ended December 31, 2016 and 2015, respectively:

	Warrant
	Liability
Balance - January 1, 2015	$	9,000
Additions during the period		15,446,000
Settlement of debt		(16,835,000)
Change in fair value of warrant liability		27,873,000
Balance – December 31, 2015	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability		(5,939,500)
Balance – December 31, 2016	$	14,500

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Note 7: FAIR VALUE MEASUREMENTS

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

Fair value measured at December 31, 2016

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Derivative liability - warrants

14,500

Fair value measured at December 31, 2015

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2015

Derivative liability - warrants

26,493,000

There were no transfers between Level 1, 2 or 3 during the year ended December 31, 2016 and 2015, respectively.

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U. S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

The net cash settlement value at the time of any future transactions, where the Company consolidates or merges with another entity, will depend upon the value of the following inputs at that time: the consideration value per share of the Company’s common stock, the volatility of the Company’s common stock, the remaining term of the warrant from announcement date, the risk-free interest rate based on U. S. Treasury security yields, and the Company’s dividend yield. The warrant requires use of a volatility assumption equal to the greater of 100% and the 100-day volatility function determined as of the trading day immediately following announcement of a Fundamental Transaction.

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of an aggregate of 3,096,665 outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements (the “Amended Warrants”) in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

The fair value of the Amended Warrants was re-measured immediately prior to the date of amendment with changes in fair value recorded as a gain of $5.1 million in the statement of operations and $15.5 million was reclassified to equity.

PROMISSORY NOTES

12 Months Ended

Dec. 31, 2016

Promissory Notes [Abstract]

PROMISSORY NOTES

Note 8:

Promissory notes

At December 31, 2016, the Company had outstanding promissory notes in the amount of $5,000 as compared to two outstanding promissory notes totaling $30,000 at December 31, 2015. The one promissory note outstanding and due at December 31, 2016 bears 10% annual interest.

PROMISSORY NOTE, RELATED PARTY

12 Months Ended

Dec. 31, 2016

Promissory Note And Related Party [Abstract]

PROMISSORY NOTE, RELATED PARTY

Note 9:

Promissory note, related party

At December 31, 2015, the Company had an outstanding promissory note in the amount of $23,000 owed to an officer of the Company. The promissory note bore no interest charges and had no fixed repayment terms. During the year ended December 31, 2016, the note was paid in full.

STOCKHOLDERS’ EQUITY

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

STOCKHOLDERS’ EQUITY

Note 10:

stockholders’ equity

Preferred Stock

The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s board of directors upon its issuance. To date, the Company has not issued any preferred shares.

Series A Preferred Stock - The Company has designated up to 1,250,000 shares of Series A Preferred Stock, $0.0001 par value per share, for issuance. To date, the Company has not issued any Series A preferred shares.

Series B Preferred Stock - The Company has designated up to 1,500,000 shares of Series B Preferred Stock, $0.0001 par value per share, for issuance. To date, the Company has not issued any Series B preferred shares.

Common Stock

The Company has authorized up to 41,666,667 shares of common stock, $0.0001 par value per share, for issuance. Significant 2016 and 2015 common stock transactions were as follows:

2016 Common Stock Transactions

Private placements

On August 10, 2016 and August 25, 2016, the Company completed private placements of units with certain accredited investors. The units consisted of (i) one share of the Company’s common stock, par value $0.001 per share and (ii) one five-year warrant to purchase one share of Company common stock for $6.00. The Company issued and sold an aggregate of 653,187 units at a purchase price per unit of $4.80 for an aggregate of approximately $3.1 million. The Company incurred approximately $0.8 million in agency fees and legal costs. The estimated fair value of the warrants was approximately $3.5 million. The fair value was estimated using inputs of : strike price of $6.00, expected term of five years, estimated volatility of 146%, risk-free rate of 1.1% and expected dividend rate of 0%.

Warrant Amendment Transaction

On August 10, 2016, the Company and holders of outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements in which they agreed to amend the terms of the outstanding series warrants to remove provisions that had previously precluded equity classification treatment on the Company’s balance sheets.

In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, the Company issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of Company common stock at an exercise price of $7.20 per share.

Warrant Exercises

On August 11, 2016, holders of an aggregate of 583,333 outstanding Series C Warrants and 416,667 Series C-1 Warrants, each providing for the purchase of one share of our common stock for $6.00 per share, exercised their warrants for an aggregate exercise price of $6,000,000.

Exercise of Stock Options

In December 2016, Dr. John Bonfiglio exercised 10,417 shares of common stock pursuant to stock options at an exercise price equal to $1.74 per share.

Debt Settlement

In May 2016, the Company issued 10,191 common shares as part of debt conversion agreements from 2014. The fair value of the common stock of approximately $70,000 was recognized as loss on debt settlement agreements in other income (expense).

2016 Management Compensation

In July 2016, the Company entered into an employment agreement with Dr. John Bonfiglio relating to his appointment as the Company’s President and Chief Operating Officer. As part of the agreement, Dr. John Bonfiglio was awarded 20,833 common shares, which will vest upon the earlier of (i) the listing of the Company’s common stock on a national securities exchange in the United States or (ii) the first anniversary of the employment agreement, so long as Dr. John Bonfiglio is employed with the Company. The fair value of the common stock of approximately $103,000 was recognized as stock-based compensation in general and administrative expense.

Consulting arrangements

During the year ended December 31, 2016, the Company issued 75,000 common shares as part of consulting agreements. The fair value of the common stock of approximately $480,000 was recognized as stock-based compensation in general and administrative expense.

2015 Common Stock Transactions

Private placements

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 610,000 units at a purchase price of $2.40 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s common stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $18.00 per share, with a five-year term. Series B warrants are exercisable at $4.80 per share, with a six-month term. Series C warrants are exercisable at $12.00 per share, with a five-year term. Series D warrants are exercisable at $9.00 per share only if and to the extent that the Series B warrants are exercised, with a five-year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $15.00 per share, only if and to the extent that the Series C warrants are exercised, with a five-year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 30,500 common shares with substantially the same terms as the January 2015 Warrants and pay a 7% finder’s fee on gross proceeds from the sale of securities.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 416,667 units at a purchase price of $2.40 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s common stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 10,417 common shares with substantially the same terms as the March 2015 Warrants and pay a 3.5% finder’s fee on gross proceeds from the sale of securities.

2015 Management Compensation

In November 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman of the Company. As part of the agreement, the Company granted Dr. Wilson 26,250 shares of unregistered common stock, fully vested. The Company recorded an obligation to deliver the shares of $191,000 based on the fair value of the common stock at December 31, 2015. The Company issued the shares in March 2016 and reclassified the accrued liability to stockholders’ equity (deficit). In the nine months ended September 30, 2016, to adjust for the withholding tax liability, which was payable in cash, Dr. Wilson returned the 26,250 fully vested common shares and was issued 19,018 fully vested common shares.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

WARRANTS

12 Months Ended

Dec. 31, 2016

Warrants Disclosure [Abstract]

WARRANTS

Note 11:

WARRANTS

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of December 31, 2016 and 2015, respectively, and changes during the period is presented below:

					Weighted Average
	Number of		Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants		Exercise Price		Life (in years)		Value
Balance - January 1, 2015		222,000	$	21.96		4.15	$	-
Issued		7,228,000		6.48		4.30
Exercised		(3,090,000)		3.00		-
Extinguished or expird		(17,000)		28.68		-
Balance - December 31, 2015		4,343,000		8.67		4.24		5,547,000
Issued		1,718,000		6.65		4.62
Exercised		(1,000,000)		6.00		-
Expired		(2,000)		287.20		-
Balance - December 31, 2016		5,059,000	$	8.49		3.68	$	1,713,000

2016 Warrant Transactions

August 2016 Warrant Exercises

August 2016 Warrant Amendments

As discussed in Note 10, Stockholders’ Equity, simultaneous with the exercise of the warrants, the Company and holders of outstanding Series A Warrants, Series A-1 Warrants, Series C Warrants, Series C-1 Warrants, Series D Warrants, Series D-1 Warrants, Series E Warrants and Series E-1 Warrants entered into warrant amendment agreements, in which they agreed to amend the terms of the existing warrant agreements to remove provisions that had previously caused them to be classified as a derivative liability as opposed to equity on our balance sheet. In consideration for such amendment and the exercise of the Series C Warrants and Series C-1 Warrants, we issued an aggregate of 750,000 additional shares of common stock to such warrant holders and new five-year warrants to purchase 1,000,000 shares of our common stock at an exercise price of $7.20 per share (the “Series F and F-1Warrants”). The value of the shares was treated as dividend on the statement of stockholders’ equity of $4.5 million. The estimated fair value of the warrants was approximately $5.4 million. The fair value was estimated using inputs of : strike price of $7.20, expected term of five years, estimated volatility of 146%, risk-free rate of 1.1% and expected dividend rate of 0%.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 65,317 shares of Company common stock for $4.80 per share. The estimated fair value of the warrants was approximately $0.4 million. The fair value was estimated using inputs of : strike price of $4.80, expected term of five years, estimated volatility of 146%, risk-free rate of 1.1% and expected dividend rate of 0%.

2015 Warrant Transactions

January 2015 Financing

In January, 2015, we entered into a Securities Purchase Agreement with certain investors for the sale of 610,000 units at a purchase price of $2.40 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants were exercisable at $18.00 per share, with a five-year term. Series B warrants were exercisable at $4.80 per share, with a six-month term. Series C warrants were exercisable at $12.00 per share, with a five-year term. Series D warrants were exercisable at $9.00 per share only if and to the extent that the Series B warrants are exercised, with a five-year term from the date that the Series B warrants are exercised. Series E warrants were exercisable at $15.00 per share, only if and to the extent that the Series C warrants are exercised, with a five-year term from the date that the Series C warrants are exercised. Pursuant to a placement agent agreement, we agreed to issue warrants to purchase 30,500 common shares with substantially the same terms as the January 2015 Warrants.

March 2015 Financing

In March, 2015, we entered into a Securities Purchase Agreement with certain accredited investors for the sale of 416,667 units at a purchase price of $2.40 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A-1 warrant to purchase one share of common stock, (iii) one Series B-1 warrant to purchase one share of common stock (iv) one Series C-1 warrant to purchase one share of common stock, (v) one Series D-1 warrant to purchase one share of common stock, and (vi) one Series E-1 warrant to purchase one share of common stock (the Series A-1, B-1, C-1, D-1 and E-1 warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants. Pursuant to a placement agent agreement, we agreed to issue warrants to purchase 10,417 common shares with substantially the same terms as the March 2015 Warrants.

Restructuring of January and March 2015 Financings

In May 2015, we entered into a restructuring agreement with the investors of the January 2015 and March 2015 financings, where:

· The exercise price of the Series A and Series A-1 warrants was changed from $18.00 per share to $1.20 per share,

· The exercise price of Series B and Series B-1 warrants was changed from $4.80 per share to $2.40 per share,

· Each warrant of Series B and Series B-1 existing prior to the restructuring agreement was replaced with two warrants of such series,

· The exercise price of the Series C and Series C-1 warrants was changed from $12.00 per share to $6.00 per share, and

· Each warrant of Series C and Series C-1 existing prior to the restructuring agreement was replaced with two warrants of such series.

As a result of the restructuring agreement, we issued an additional 1,026,667 Series B and B-1 warrants and 1,026,667 Series C and C-1 Warrants.

The following table reflects the status of the outstanding warrants from the January 2015, March 2015, and August 2016 private placement financings (including placement agent warrants) following the Amendment Agreement and private placement:

Series	Outstanding Warrants		Exercise Price		Expiration
A		214,433	$	1.20	01/13/2020
C		424,433	$	6.00	01/13/2020
D		610,000	$	9.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
E		616,100	$	15.00	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
A-1		418,750	$	1.20	03/09/2020
C-1		2,083	$	6.00	01/13/2020
D-1		416,667	$	9.00	Between 08/19/2020 and 09/09/2020
E-1		418,750	$	15.00	06/16/2020
F		583,333	$	7.20	08/11/2021
F-1		416,667	$	7.20	08/11/2021
PIPE Warrants		653,187	$	6.00	08/11/2021
Broker Warrants		65,327	$	4.80	08/11/2021

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Note 12:

stock-based compensation

Options to Purchase Shares of Common Stock

2009 Stock Omnibus Plan

On October 14, 2009, the Company adopted the 2009 Stock Incentive Plan (the “2009 Plan”). The 2009 Plan allows for the issuance of up to 8,333 common shares. Options granted under the Plan shall be at prices and for terms as determined by our Board of Directors, and may have vesting requirements as determined by our Board of Directors. The foregoing summary of the 2009 Plan is not complete and is qualified in its entirety by reference to the 2009 Stock Incentive Plan, a copy of which has been filed with the SEC. To date, 3,679 options have been issued under the 2009 Plan, of which 2,013 are outstanding.

2014 Stock Omnibus Plan

On March 19, 2014, the Board adopted the 2014 Omnibus Stock Option Plan (“2014 Plan”). The 2014 Plan allowed for grants of stock options, restricted shares, stock bonuses and other equity based awards to employees and non-employee directors of the Company. Awards under the 2014 Plan may be at prices and for terms as determined by the Board of Directors, and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2014 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company’s stockholders, other than under certain limited circumstances such as a stock split, or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the New York Stock Exchange. Under the 2014 as originally approved, stock could be issued under the 2014 Plan as a bonus to any employee, other than executive officers of the Company and 166,667 shares of common stock were reserved for issuance under the 2014 Plan. The 2014 Plan was amended in February 2015 to provide for grants to consultants, and again in November 2015 to (i) increase the number of shares reserved for issuance under the Plan by 416,667 shares to 583,334 shares; (ii) provide the Board and Committee administering the Plan with full discretion on the vesting period for Service-Vesting Awards under the Plan, including the grant of Awards with less than the Minimum Vesting Requirement (as such terms are defined in the Plan), and (iii) provide the Board and Committee administering the Plan with the ability to grant stock bonuses to executive officers. To date, 442,500 options have been issued under the 2014 Plan.

Stock Options

A summary of the Company’s stock option activity is as follows for stock options:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Total Intrinsic Value
Outstanding as of December 31, 2014		5,453	$	215.26		3.4	$	-
Options granted		295,000		6.65		9.8		177,000
Forfeited/expired		(1,774)		-		-		-
Outstanding as of December 31, 2015		298,679		9.22		9.7		177,000
Options granted		147,500		5.84		9.3		-
Exercised		(10,417)		1.74		-		-
Forfeited/expired		(1,667)		228.00		-		-
Outstanding as of December 31, 2016		434,095	$	7.41		8.9		39,000
Options vested and exercisable		281,209	$	8.03		8.7		38,000

The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company’s share-based compensation plans. The weighted average average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2016, 2015, respectively, were as follows:

	For the years ended
	December 31,
	2016			2015
Exercise price	$	5.84		$	6.65
Expected term (years)		9.7			9.1
Expected stock price volatility		237.7	%		230.0	%
Risk-free rate of interest		1.6	%		2.1	%
Expected dividend rate		0	%		0	%

The Company recorded $1,558,409 and $1,705,067 of stock-based compensation expense for the years ended December 31, 2016 and 2015, respectively.

Total stock-based compensation cost related to unvested awards not yet recognized and the weighted average periods over which the awards are expected to be recognized as of December 31, 2016 are as follows:

Unrecognized stock-based compensation cost:		$	954,000
Expected weighted average period compensation costs to be recognized (years):			0.84

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

GRANT INCOME

12 Months Ended

Dec. 31, 2016

Text Block [Abstract]

GRANT INCOME

Note 13:

grant income

During the year ended December 31, 2016, the Company received approximately $231,000 of grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV 200. The grant paid for the clinical supplies purchased by the Company.

CONTINGENCIES AND COMMITMENTS

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES AND COMMITMENTS

Note 14:

ContingencIES AND COMMITMENTs

Employment Agreements

On November 12, 2015, the Company entered into an employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer. In connection with Dr. Wilson’s appointment, he entered into an employment agreement with the Company. The employment agreement provides that Dr. Wilson’s base salary will be $280,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Dr. Wilson or the Company.

On July 18, 2016, the Company appointed Dr. John Bonfiglio as the Company’s President and Chief Operating Officer. In connection with Dr. Bonfiglio’s appointment, he entered into an employment agreement with the Company. The employment agreement provides that Dr. Bonfiglio’s base salary will be $260,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Dr. Bonfiglio or the Company.

On August 25, 2016, the Company appointed Michael J. Loiacono as the Company’s Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer. In connection with Mr. Loiacono’s appointment, he entered into an employment agreement with the Company. The employment agreement provides that Mr. Loiacono’s base salary will be $200,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. The term of the employment agreement is for two years and will be automatically extended for an additional 12 months unless terminated by Mr. Loiacono or the Company.

Leased facilities

We have multiple month-to-month leases that aggregate approximately $3,000 per month. Our principal business office lease agreement expires in July 2017 and the rent is approximately $3,500 per month.

The minimum rental payments required for 2017 under the operating office leases as of December 31, 2016 was approximately $38,700.

LEGAL PROCEEDINGS

12 Months Ended

Dec. 31, 2016

Disclosure Text Block Supplement [Abstract]

LEGAL PROCEEDINGS

Note 15:

LEGAL PROCEEDINGS

From time to time, the Company may be party to ordinary, routine litigation incidental to their business. We know of no material, active or pending legal proceedings against the Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

INCOME TAXES

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 16:

INCOME TAXES

The Company has no income tax expense due to operating losses incurred for the years ended December 31, 2016 and 2015. Approximately $380,000 in non-qualified stock options were cancelled during 2016 due to terminations that resulted in a reversal of the deferred tax asset of approximately $140,000. The cancellations did not result in a book income for December 31, 2016.

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2016 and 2015 are as follows:

	For the years ended
	December 31,
	2016		2015
Deferred tax assets:
Net operating loss carryforward	$	10,934,000	$	8,359,000
Stock-based compensation		2,066,000		1,897,000
License agreements		490,000		268,000
Research and development		117,000		117,000
Technology licensing fee		185,000		185,000
Valuation allowance		(13,792,000)		(10,826,000)
Deferred tax assets, net of valuation allowance	$	-	$	-

The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2016 and 2015. The valuation allowance increased by $3.0 million as of December 31, 2016. The Company has research and development tax credit carryforwards of $117,000 to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2029.

The Company has approximately $31,000,000 of federal and $11,200,000 of state Net Operating Loss (“NOL”s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards, if not utilized, will expire between 2029 and 2036. The state net operating loss carryforwards, if not utilized, will expire in 2036.

In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section 382 analysis has not been prepared and NOLs could be subject to limitation under Section 382.

For the years ended December 31, 2016 and 2015, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the years ended
	December 31,
	2016		2015
U. S. federal statutory rate	$	(835,000)	$	(11,582,000)
State taxes, net of federal benefit		(286,000)		(199,000)

Permanent differences
- Change in fair value of derivative liabilities		(2,019,000)		9,477,000
- Write off of net operating loss		-		3,591,000
-Other permanent differences		46,000		12,000
Change in valuation allowance		2,966,000		(1,645,000)
Other		128,000		346,000
Income tax provision (benefit)	$	-	$	-

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2016 and 2015, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2016 and 2015. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

	For the years ended
	December 31,
	2016			2015
U. S. federal statutory rate		(34.0)	%		(34.0)	%
State taxes, net of federal benefit		(11.6)	%		(0.6)	%

Permanent differences
- Change in fair value of derivative liabilities		(82.2)	%		27.8	%
- Write off of net operating loss		0.0	%		10.5	%
-Other permanent differences		1.9	%		0.0	%
Change in valuation allowance		120.8	%		(4.8)	%
Other		5.2	%		1.0	%
Income tax provision (benefit)		0.0	%		0.0	%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

These financial statements are presented in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Fair Value Measurements

Fair Value Measurements

•

Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities.

•

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial Instruments and Concentration of Credit Risk.

Patents and Patent Application Costs

Patents and Patent Application Costs

Stock-Based Compensation

Stock-Based Compensation

Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Research and Development Costs

Research and Development Costs

The Company incurred costs of approximately $3,800,000 and $1,711,000 on research and development for the year ended December 31, 2016 and 2015, respectively.

Income Taxes

Income Taxes

Derivative Liability

Derivative Liability

Grant Income

Grant Income

Earnings (Loss) Per Common Share

Earnings (Loss) per Common Share

Cash and Credit Risk

Cash and Credit Risk

New Accounting Pronouncements

New Accounting Pronouncements

Statement of Cash Flows

Going Concern

Deferred Taxes

Compensation-Stock Compensation

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)

12 Months Ended

Dec. 31, 2016

Noncontrolling Interest [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of loss per share for the years ended December 31, 2016 and 2015, respectively:

	For the years ended
	December 31,
	2016		2015
Net loss	$	(2,455,381)	$	(34,066,390)
Less: Non cash income from changes in fair value of derivative liabilities		(2,856,000)		-
Net loss - diluted	$	(5,311,381)	$	(34,066,390)

Weighted average common shares outstanding - basic		6,889,898		3,662,256
Common stock warrants		531,097		-
Weighted average common shares outstanding - diluted		7,420,995		3,662,256

Net loss per share data:
Basic	$	(0.36)	$	(9.30)
Diluted	$	(0.72)	$	(9.30)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	For the years ended
	December 31,
	2016		2015
Common stock options		434,000		299,000
Common stock warrants - equity treatment		5,054,000		212,000
Common stock warrants - liability treatment		4,000		4,130,000
Potentially dilutive securities		5,492,000		4,641,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following as of December 31, 2016 and 2015, respectively:

	For the years ended
	December 31,
	2016		2015
Accounts payable	$	680,181	$	691,094
Compensation and benefits		217,622		191,000
Professional fees		53,428		15,000
Consulting agreements		94,576		-
Technology license fees		105,000		-
Other		74,133		70,264
Total accounts payable and accrued liabilities	$	1,224,940	$	967,358

WARRANT LIABILITY (Tables)

12 Months Ended

Dec. 31, 2016

Warrant Liability [Abstract]

Valuation Methodology

Stock Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Year Ending December 31, 2016			For the Year Ending December 31, 2015
Exercise price	$	1.20		$	0.74
Contractual term (years)		1.15			4.2
Volatility (annual)		100	%		155	%
Risk-free rate		1.00	%		2.00	%
Dividend yield (per share)		0	%		0	%

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 warrant liabilities measured at fair value for the year ended December 31, 2016 and 2015, respectively:

	Warrant
	Liability
Balance - January 1, 2015	$	9,000
Additions during the period		15,446,000
Settlement of debt		(16,835,000)
Change in fair value of warrant liability		27,873,000
Balance – December 31, 2015	$	26,493,000
Reclassification of derivative liabilities to equity at exercise date		(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements		(15,465,000)
Change in fair value of warrant liability		(5,939,500)
Balance – December 31, 2016	$	14,500

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Financial Assets And Liabilities Measured At Fair Value On Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:

Fair value measured at December 31, 2016

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Derivative liability - warrants

14,500

Fair value measured at December 31, 2015

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2015

Derivative liability - warrants

26,493,000

WARRANTS (Tables)

12 Months Ended

Dec. 31, 2016

Warrants Disclosure [Abstract]

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of December 31, 2016 and 2015, respectively, and changes during the period is presented below:

					Weighted Average
	Number of		Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants		Exercise Price		Life (in years)		Value
Balance - January 1, 2015		222,000	$	21.96		4.15	$	-
Issued		7,228,000		6.48		4.30
Exercised		(3,090,000)		3.00		-
Extinguished or expird		(17,000)		28.68		-
Balance - December 31, 2015		4,343,000		8.67		4.24		5,547,000
Issued		1,718,000		6.65		4.62
Exercised		(1,000,000)		6.00		-
Expired		(2,000)		287.20		-
Balance - December 31, 2016		5,059,000	$	8.49		3.68	$	1,713,000

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Series	Outstanding Warrants		Exercise Price		Expiration
A		214,433	$	1.20	01/13/2020
C		424,433	$	6.00	01/13/2020
D		610,000	$	9.00	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
E		616,100	$	15.00	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
A-1		418,750	$	1.20	03/09/2020
C-1		2,083	$	6.00	01/13/2020
D-1		416,667	$	9.00	Between 08/19/2020 and 09/09/2020
E-1		418,750	$	15.00	06/16/2020
F		583,333	$	7.20	08/11/2021
F-1		416,667	$	7.20	08/11/2021
PIPE Warrants		653,187	$	6.00	08/11/2021
Broker Warrants		65,327	$	4.80	08/11/2021

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Activity

A summary of the Company’s stock option activity is as follows for stock options:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)		Total Intrinsic Value
Outstanding as of December 31, 2014		5,453	$	215.26		3.4	$	-
Options granted		295,000		6.65		9.8		177,000
Forfeited/expired		(1,774)		-		-		-
Outstanding as of December 31, 2015		298,679		9.22		9.7		177,000
Options granted		147,500		5.84		9.3		-
Exercised		(10,417)		1.74		-		-
Forfeited/expired		(1,667)		228.00		-		-
Outstanding as of December 31, 2016		434,095	$	7.41		8.9		39,000
Options vested and exercisable		281,209	$	8.03		8.7		38,000

Schedule or Description of Weighted Average Discount Rate

	For the years ended
	December 31,
	2016			2015
Exercise price	$	5.84		$	6.65
Expected term (years)		9.7			9.1
Expected stock price volatility		237.7	%		230.0	%
Risk-free rate of interest		1.6	%		2.1	%
Expected dividend rate		0	%		0	%

Schedule of Unrecognized Compensation Cost, Nonvested Awards

Unrecognized stock-based compensation cost:		$	954,000
Expected weighted average period compensation costs to be recognized (years):			0.84

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities

The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2016 and 2015 are as follows:

	For the years ended
	December 31,
	2016		2015
Deferred tax assets:
Net operating loss carryforward	$	10,934,000	$	8,359,000
Stock-based compensation		2,066,000		1,897,000
License agreements		490,000		268,000
Research and development		117,000		117,000
Technology licensing fee		185,000		185,000
Valuation allowance		(13,792,000)		(10,826,000)
Deferred tax assets, net of valuation allowance	$	-	$	-

Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit

For the years ended December 31, 2016 and 2015, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:

	For the years ended
	December 31,
	2016		2015
U. S. federal statutory rate	$	(835,000)	$	(11,582,000)
State taxes, net of federal benefit		(286,000)		(199,000)

Permanent differences
- Change in fair value of derivative liabilities		(2,019,000)		9,477,000
- Write off of net operating loss		-		3,591,000
-Other permanent differences		46,000		12,000
Change in valuation allowance		2,966,000		(1,645,000)
Other		128,000		346,000
Income tax provision (benefit)	$	-	$	-

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the Company’s effective tax rate to the statutory U.S. federal rate is as follows:

	For the years ended
	December 31,
	2016			2015
U. S. federal statutory rate		(34.0)	%		(34.0)	%
State taxes, net of federal benefit		(11.6)	%		(0.6)	%

Permanent differences
- Change in fair value of derivative liabilities		(82.2)	%		27.8	%
- Write off of net operating loss		0.0	%		10.5	%
-Other permanent differences		1.9	%		0.0	%
Change in valuation allowance		120.8	%		(4.8)	%
Other		5.2	%		1.0	%
Income tax provision (benefit)		0.0	%		0.0	%

NATURE OF OPERATIONS - Additional Information (Detail)		12 Months Ended
NATURE OF OPERATIONS - Additional Information (Detail)	Sep. 13, 2016	Dec. 31, 2016 USD ($) Patient	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Number of ovarian cancer patients \| Patient		30,000
Percentage of breast cancers		50.00%
Percentage of ovarian cancers		95.00%
Stockholders' Equity, Reverse Stock Split	1-for-12
Cash \| $		$ 7,851,243	$ 6,576,564	$ 141,944

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Research and Development Expense	$ 3,800,035	$ 1,711,177
Cash, FDIC Insured Amount	250,000
Cash, Uninsured Amount	$ 7,600,000	$ 6,300,000

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (2,455,381)	$ (34,066,390)
Less: Non cash income from changes in fair value of derivative liabilities	(2,856,000)	0
Net loss - diluted	$ (5,311,381)	$ (34,066,390)
Weighted average common shares outstanding - basic	6,889,898	3,662,256
Common stock warrants	531,097
Weighted average common shares outstanding - diluted	7,420,995	3,662,256
Net loss per share data:
Basic	$ (0.36)	$ (9.3)
Diluted	$ (0.72)	$ (9.3)

NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Common stock options	434,000	299,000
Common stock warrants - equity treatment	5,054,000	212,000
Common stock warrants - liability treatment	4,000	4,130,000
Potentially dilutive securities	5,492,000	4,641,000

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES -Accounts payable and accrued liabilities (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts Payable And Accrued Liabilities [Line Items]
Accounts payable	$ 680,181	$ 691,094
Compensation and benefits	217,622	191,000
Professional fees	53,428	15,000
Consulting agreements	94,576	0
Technology license fees	105,000	0
Other	74,133	70,264
Total accounts payable and accrued liabilities	$ 1,224,940	$ 967,358

RESEARCH AGREEMENTS - Additional Information (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued Liabilities	$ 492,000	$ 492,000

WARRANT LIABILITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.2	$ 0.74
Contractual term (years)	1 year 1 month 24 days	4 years 2 months 12 days
Volatility (annual)	100.00%	155.00%
Risk-free rate	1.00%	2.00%
Dividend yield (per share)	0.00%	0.00%

WARRANT LIABILITY - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Balance	$ 26,493,000	$ 9,000
Additions during the period		15,446,000
Settlement of debt		(16,835,000)
Reclassification of derivative liabilities to equity at exercise date	(5,074,000)
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	(15,465,000)
Change in fair value of warrant liability	(5,939,500)	27,873,000
Balance	$ 14,500	$ 26,493,000

FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	0	0
Significant other observable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	14,500	26,493,000
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 14,500	$ 26,493,000

FAIR VALUE MEASUREMENTS - Additional Information (Detail) - USD ($) $ in Millions		12 Months Ended
	Aug. 10, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Outstanding	3,096,665	5,059,000	4,343,000	222,000
Class Of Warrant Or Right Expiration Period	5 years
Derivative, Gain on Derivative		$ 5.1
Fair Value Of Warrant Reclassification To Equity		$ 15.5

PROMISSORY NOTES - Additional Information (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Outstanding promissory notes	$ 5,000	$ 30,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	10.00%

PROMISSORY NOTE, RELATED PARTY - Additional Information (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Outstanding promissory notes	$ 0	$ 23,000

STOCKHOLDERS’ EQUITY - Additional Information (Detail)			1 Months Ended							9 Months Ended	12 Months Ended
STOCKHOLDERS’ EQUITY - Additional Information (Detail)	Aug. 11, 2016 USD ($) $ / shares shares	Aug. 10, 2016 $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Aug. 31, 2016 USD ($) $ / shares $ / Unit shares	Jul. 31, 2016 shares	May 31, 2016 USD ($) shares	Nov. 30, 2015 shares	Mar. 31, 2015 USD ($) $ / Unit shares	Jan. 31, 2015 USD ($) $ / shares $ / Unit shares	Sep. 30, 2016 shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $											$ 103,000
Common shares issued						10,191
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001								$ 0.001	$ 0.001
Class Of Warrant Or Right Expiration Period		5 years
Number Of Equity Unit Issued								416,667
Equity Unit Issued Price Per Unit \| $ / Unit								2.40
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $								$ 950,000
Gain (Loss) on Extinguishment of Debt \| $						$ 70,000					$ (135,640)	$ (24,697)
Class of Warrant or Right, Outstanding		3,096,665	5,059,000								5,059,000	4,343,000	222,000
Preferred Stock, Shares Authorized			5,000,000								5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001								$ 0.001	$ 0.001
Common Stock, Shares Authorized			41,666,667								41,666,667	41,666,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											10,417
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares											$ 1.74
Warrants Issued Finders Fee And Offering Costs \| $								$ 50,000
Proceeds from Warrant Exercises \| $											$ 6,000,000	$ 9,219,998
Series A Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.20								$ 1.20
Class of Warrant or Right, Outstanding			214,433								214,433
Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 6.00		$ 6.00								$ 6.00
Class of Warrant or Right, Outstanding	583,333		424,433								424,433
Proceeds from Warrant Exercises \| $	$ 6,000,000
Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 9.00								$ 9.00
Class of Warrant or Right, Outstanding			610,000								610,000
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								10,417	30,500
Percentage Of Finders Fee								3.50%	7.00%
Series C-1 Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000
Class of Warrant or Right, Outstanding	416,667
Stock Issued During Period Shares, Upon Exercise Of Warrants		750,000
Series A Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred Stock, Shares Authorized			1,250,000								1,250,000	1,250,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001								$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Preferred Stock, Shares Authorized			1,500,000								1,500,000	1,500,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001								$ 0.001	$ 0.001
Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					20,833
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 6.00					$ 15.00
Class Of Warrant Or Right Expiration Period									5 years
Legal Fees \| $				$ 800,000
Number Of Equity Unit Issued				653,187					610,000
Equity Unit Issued Price Per Unit \| $ / Unit				4.80					2.40
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchases Agreement \| $				$ 3,100,000					$ 1,250,000
Class of Warrant or Right, Outstanding				65,317
Warrants Issued Finders Fee And Offering Costs \| $									$ 214,000
Private Placement [Member] \| Series A Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 18.00
Class Of Warrant Or Right Expiration Period									5 years
Private Placement [Member] \| Series B Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 4.80
Class Of Warrant Or Right Expiration Period									6 months
Private Placement [Member] \| Series C Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 12.00
Class Of Warrant Or Right Expiration Period									5 years
Private Placement [Member] \| Series D Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 9.00
Class Of Warrant Or Right Expiration Period									5 years
Private Placement [Member] \| Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure \| $			$ 3,500,000								$ 3,500,000
Fair Value Assumptions, Exercise Price \| $ / shares			$ 6.00								$ 6.00
Fair Value Assumptions, Expected Volatility Rate											146.00%
Fair Value Assumptions, Risk Free Interest Rate											1.10%
Fair Value Assumptions, Expected Dividend Rate											0.00%
Fair Value Assumptions, Expected Term											5 years
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock \| $											$ 480,000
Common shares issued											75,000
Chief Executive Officer, President and Chairman [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			10,417
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares			$ 1.74
Chief Executive Officer, President and Chairman [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period										19,018
Deferred Compensation Arrangement with Individual, Shares Issued							26,250
Deferred Compensation Arrangement with Individual, Recorded Liability \| $												$ 191,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period										26,250
Placement Agent [Member] \| Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class Of Warrant Or Right Expiration Period				5 years

WARRANTS - Share Purchase Warrants (Detail) - USD ($)	12 Months Ended
WARRANTS - Share Purchase Warrants (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Warrants, Beginning balance	4,343,000	222,000
Number of Warrants, Issued	1,718,000	7,228,000
Number of Warrants, Exercised	(1,000,000)	(3,090,000)
Number of Warrants, Extinguished or expird	(2,000)	(17,000)
Number of Warrants, Ending balance	5,059,000	4,343,000	222,000
Weighted Average Exercise Price, Beginning Balance	$ 8.67	$ 21.96
Weighted Average Exercise Price, Issued	6.65	6.48
Weighted Average Exercise Price, Exercised	6.00	3.00
Weighted Average Exercise Price, Extinguished or expird	287.20	28.68
Weighted Average Exercise Price, Ending Balance	$ 8.49	$ 8.67	$ 21.96
Weighted Average Remaining Contractual Life, Outstanding (in years)	3 years 8 months 5 days	4 years 2 months 26 days	4 years 1 month 24 days
Weighted Average Remaining Contractual Life, Issued (in years)		4 years 7 months 13 days	4 years 3 months 18 days
Total Intrinsic Value, Beginning balance	$ 5,547,000	$ 0
Total Intrinsic Value, Ending balance	$ 1,713,000	$ 5,547,000	$ 0

WARRANTS-Amendment Agreement and private placement (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Aug. 11, 2016	Aug. 10, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right, Outstanding	5,059,000		3,096,665	4,343,000	222,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding	214,433
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.20
Class Of Warrant Or Right expiration Date	01/13/2020
Series C Warrant [Member]
Class of Warrant or Right, Outstanding	424,433	583,333
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.00	$ 6.00
Class Of Warrant Or Right expiration Date	01/13/2020
Series D Warrant [Member]
Class of Warrant or Right, Outstanding	610,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.00
Class Of Warrant Or Right expiration Date	Between 07/16/2020 and 08/13/2020 and 08/19/2020 and 09/09/2020
Series E Warrant [Member]
Class of Warrant or Right, Outstanding	616,100
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.00
Class Of Warrant Or Right expiration Date	Between 10/01/2020 and 11/12/2020 and 11/30/2020 and 12/09/2020
Series A-1 Warrant [Member]
Class of Warrant or Right, Outstanding	418,750
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.20
Class Of Warrant Or Right expiration Date	03/09/2020
Series C-1 Warrant [Member]
Class of Warrant or Right, Outstanding	2,083
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.00
Class Of Warrant Or Right expiration Date	01/13/2020
Series D-1 Warrant [Member]
Class of Warrant or Right, Outstanding	416,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.00
Class Of Warrant Or Right expiration Date	Between 08/19/2020 and 09/09/2020
Series E-1 Warrant [Member]
Class of Warrant or Right, Outstanding	418,750
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.00
Class Of Warrant Or Right expiration Date	06/16/2020
Series F Warrant [Member]
Class of Warrant or Right, Outstanding	583,333
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.20
Class Of Warrant Or Right expiration Date	08/11/2021
Series F-1 Warrant [Member]
Class of Warrant or Right, Outstanding	416,667
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.20
Class Of Warrant Or Right expiration Date	08/11/2021
PIPE Warrants [Member]
Class of Warrant or Right, Outstanding	653,187
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.00
Class Of Warrant Or Right expiration Date	08/11/2021
Broker Warrants [Member]
Class of Warrant or Right, Outstanding	65,327
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.80
Class Of Warrant Or Right expiration Date	08/11/2021

WARRANTS- Additional Information (Detail)			1 Months Ended		12 Months Ended
WARRANTS- Additional Information (Detail)	Aug. 11, 2016 USD ($) $ / shares shares	Aug. 10, 2016 shares	Mar. 31, 2015 USD ($) $ / Unit shares	Jan. 31, 2015 USD ($) $ / shares $ / Unit shares	Dec. 31, 2016 USD ($) $ / shares shares	Aug. 31, 2016 $ / shares shares	Dec. 31, 2015 shares	May 31, 2015 $ / shares	Dec. 31, 2014 shares
Class of Warrant or Right, Outstanding		3,096,665			5,059,000		4,343,000		222,000
Number Of Equity Units Issued			416,667
Equity Units Issued Price Per Unit \| $ / Unit			2.40
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchase Agreement \| $			$ 950,000
Warrants Issued Finders Fee And Offering Costs \| $			$ 50,000
Class Of Warrant Or Right Expiration Period		5 years
Private Placement [Member]
Class of Warrant or Right, Outstanding						65,317
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 15.00		$ 6.00
Number Of Equity Units Issued				610,000
Equity Units Issued Price Per Unit \| $ / Unit				2.40
Aggregate Purchase Price Of Shares Agreed To Purchase Under Stock Purchase Agreement \| $				$ 1,250,000
Warrants Issued Finders Fee And Offering Costs \| $				$ 214,000
Class Of Warrant Or Right Expiration Period				5 years
Private Placement [Member] \| Warrant [Member] \| Placement Agent Member
Warrants Not Settleable in Cash, Fair Value Disclosure \| $					$ 400,000
Fair Value Assumptions, Exercise Price \| $ / shares					$ 4.80
Fair Value Assumptions, Expected Volatility Rate					146.00%
Fair Value Assumptions, Risk Free Interest Rate					1.10%
Fair Value Assumptions, Expected Dividend Rate					0.00%
Fair Value Assumptions, Expected Term					5 years
August 2016 Warrant Amendments [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 7.20
Stock Issued During Period, Shares, New Issues	750,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000
Class of Warrant or Right Term	5 years
Dividends \| $	$ 4,500,000
August 2016 Warrant Amendments [Member] \| Warrant [Member]
Warrants Not Settleable in Cash, Fair Value Disclosure \| $					$ 5,400,000
Fair Value Assumptions, Exercise Price \| $ / shares					$ 7.20
Fair Value Assumptions, Expected Volatility Rate					146.00%
Fair Value Assumptions, Risk Free Interest Rate					1.10%
Fair Value Assumptions, Expected Dividend Rate					0.00%
Fair Value Assumptions, Expected Term					5 years
August 2016 Warrant Exercises [Member]
Class of Warrant or Right, Aggregate Exercise Price of Warrants or Rights \| $	$ 6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 6.00
Series C Warrants [Member]
Class of Warrant or Right, Outstanding					1,026,667
Series C Warrants [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 12.00				$ 12.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Class Of Warrant Or Right Expiration Period				5 years
Series C Warrants [Member] \| August 2016 Warrant Exercises [Member]
Class of Warrant or Right, Outstanding	583,333
Series C-1 Warrant [Member]
Class of Warrant or Right, Outstanding					2,083
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 6.00
Series C-1 Warrant [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								6.00
Series C-1 Warrant [Member] \| August 2016 Warrant Exercises [Member]
Class of Warrant or Right, Outstanding	416,667
Series B and B-1 Warrants [Member]
Class of Warrant or Right, Outstanding					1,026,667
Series B and B-1 Warrants [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								2.40
Series C and C-1 Warrants [Member]
Class of Warrant or Right, Outstanding					1,026,667
Series A Warrants [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 18.00				18.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Class Of Warrant Or Right Expiration Period				5 years
Series B Warrants [Member]
Class of Warrant or Right, Outstanding					1,026,667
Series B Warrants [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 4.80				4.80
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Class Of Warrant Or Right Expiration Period				6 months
Series D Warrant [Member]
Class of Warrant or Right, Outstanding					610,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 9.00
Series D Warrant [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 9.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Class Of Warrant Or Right Expiration Period				5 years
Series E Warrant [Member]
Class of Warrant or Right, Outstanding					616,100
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 15.00
Series E Warrant [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 15.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				1
Class Of Warrant Or Right Expiration Period				5 years
Subsequent Warrant Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			10,417	30,500
Series A-1 Warrants [Member] \| Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								$ 1.20

STOCK-BASED COMPENSATION - Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Shares Outstanding, Begining Balance	298,679	5,453
Number of Shares, Granted	147,500	295,000
Number of Shares, Exercised	(10,417)
Number of Shares, Forfeited/expired	(1,667)	(1,774)
Number of Shares Outstanding, Ending Balance	434,095	298,679	5,453
Number of Shares, Options vested and exercisable	281,209
Weighted Average Exercise Price per Share Outstanding, Begining Balance	$ 9.22	$ 215.26
Weighted Average Exercise Price per Share, Granted	5.84	6.65
Weighted Average Exercise Price per Share, Exercised	1.74
Weighted Average Exercise Price per Share, Forfeited/expired	228.00	0
Weighted Average Exercise Price per Share Outstanding, Ending Balance	7.41	$ 9.22	$ 215.26
Weighted Average Exercise Price per Share Exercisable	$ 8.03
Total Intrinsic Value Granted	$ 0	$ 177,000
Total Intrinsic Value Outstanding	39,000	$ 177,000	$ 0
Total Intrinsic Value, Exercisable	$ 38,000
Weighted Average Remaining Contractual Life, Outstanding	8 years 10 months 24 days	9 years 8 months 12 days	3 years 4 months 24 days
Weighted Average Remaining Contractual Life, Options granted		9 years 3 months 18 days	9 years 9 months 18 days
Weighted Average Remaining Contractual Life, Exercisable	8 years 8 months 12 days

STOCK-BASED COMPENSATION - Weighted Average Assumptions (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Exercise price	$ 5.84	$ 6.65
Expected term (years)	9 years 8 months 12 days	9 years 1 month 6 days
Expected stock price volatility	237.70%	230.00%
Risk-free rate of interest	1.60%	2.10%
Expected dividend rate	0.00%	0.00%

STOCK-BASED COMPENSATION - Cost Related to Unvested Awards Not Yet Recognized and the Weighted Average Periods (Detail)	12 Months Ended
	Dec. 31, 2016 USD ($)
Unrecognized stock-based compensation cost:	$ 954,000
Expected weighted average period compensation costs to be recognized (years):	10 months 2 days

STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Oct. 14, 2009	Nov. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 19, 2014
Share-based Compensation			$ 1,558,409	$ 1,705,067
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						166,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			434,095	298,679	5,453
Stock Incentive Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	8,333
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	3,679
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,013
Omnibus Stock Option Plan 2014 [Member]
Share-based Compensation			$ 1,558,409	$ 1,705,067
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		583,334
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period			442,500
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		416,667

GRANT INCOME - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue from Grants	$ 231,200	$ 0

CONTINGENCIES AND COMMITMENTS - Additional Information (Detail) - USD ($)			1 Months Ended		12 Months Ended
	Jul. 18, 2016	Nov. 12, 2015	Aug. 25, 2016	Jul. 18, 2016	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense					$ 3,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months					38,700
Business Office Lease [Member]
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense					$ 3,500
Lease Expiration Date					Jul. 31, 2017
Chief Operating Officer [Member]
Commitments And Contingencies [Line Items]
Salaries, Wages and Officers' Compensation	$ 260,000	$ 280,000	$ 200,000
Annual Performance Bonus On Base Salary Percentage Eligible		50.00%	50.00%	50.00%

INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforward	$ 10,934,000	$ 8,359,000
Stock-based compensation	2,066,000	1,897,000
License agreements	490,000	268,000
Research and development	117,000	117,000
Technology licensing fee	185,000	185,000
Valuation allowance	(13,792,000)	(10,826,000)
Deferred tax assets, net of valuation allowance	$ 0	$ 0

INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
U. S. federal statutory rate	$ (835,000)	$ (11,582,000)
State taxes, net of federal benefit	(286,000)	(199,000)
Permanent differences
Permanent differences- Change in fair value of derivative liabilities	(2,019,000)	9,477,000
Permanent differences- Write off of net operating loss	0	3,591,000
Permanent differences- Other permanent differences	46,000	12,000
Change in valuation allowance	2,966,000	(1,645,000)
Other	128,000	346,000
Income tax provision (benefit)	$ 0	$ 0

INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
U. S. federal statutory rate	(34.00%)	(34.00%)
State taxes, net of federal benefit	(11.60%)	(0.60%)
Permanent differences
- Change in fair value of derivative liabilities	(82.20%)	27.80%
- Write off of net operating loss	0.00%	10.50%
-Other permanent differences	1.90%	0.00%
Change in valuation allowance	120.80%	(4.80%)
Other	5.20%	1.00%
Income tax provision (benefit)	0.00%	0.00%

INCOME TAXES - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Stock Granted, Value, Share-based Compensation, Forfeited	$ 380,000
Reversal of deferred tax assets	$ 140,000
Tax credit carryforwards expiration period	2029
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 117,000	$ 117,000
Tax credit carryforwards expiration year end	2036
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	$ 31,000,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	11,200,000
Income Tax Examination, Penalties and Interest Accrued	0	0
Unrecognized Tax Benefits	0	0
Income Tax Expense (Benefit)	0	0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 2,966,000	$ (1,645,000)
Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax credit carryforwards expiration period	2029